Citigroup Inc. trimmed its position in USANA Health Sciences, Inc. (NYSE:USNA) by 27.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,303 shares of the company’s stock after selling 1,964 shares during the period. Citigroup Inc.’s holdings in USANA Health Sciences were worth $456,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Swiss National Bank boosted its holdings in USANA Health Sciences by 10.1% in the 4th quarter. Swiss National Bank now owns 19,600 shares of the company’s stock valued at $1,451,000 after purchasing an additional 1,800 shares during the period. UBS Asset Management Americas Inc. bought a new position in USANA Health Sciences in the 4th quarter valued at $478,000. Fort L.P. boosted its holdings in USANA Health Sciences by 7,199.2% in the 4th quarter. Fort L.P. now owns 52,189 shares of the company’s stock valued at $3,865,000 after purchasing an additional 51,474 shares during the period. Teacher Retirement System of Texas bought a new position in USANA Health Sciences in the 4th quarter valued at $282,000. Finally, Teachers Advisors LLC boosted its holdings in USANA Health Sciences by 1.2% in the 4th quarter. Teachers Advisors LLC now owns 211,824 shares of the company’s stock valued at $15,686,000 after purchasing an additional 2,506 shares during the period. 48.39% of the stock is owned by hedge funds and other institutional investors.
USANA Health Sciences opened at $118.95 on Tuesday, according to Marketbeat Ratings. USANA Health Sciences, Inc. has a 52-week low of $52.80 and a 52-week high of $121.15. The firm has a market cap of $2.86 billion, a PE ratio of 29.30 and a beta of 0.73.
USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, April 24th. The company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.14. USANA Health Sciences had a net margin of 6.47% and a return on equity of 27.92%. The company had revenue of $292.00 million during the quarter, compared to the consensus estimate of $268.93 million. During the same period in the previous year, the firm posted $0.91 EPS. The firm’s revenue was up 14.4% compared to the same quarter last year. research analysts predict that USANA Health Sciences, Inc. will post 4.4 earnings per share for the current fiscal year.
A number of analysts have recently issued reports on the stock. TheStreet raised shares of USANA Health Sciences from a “c+” rating to an “a-” rating in a report on Tuesday, April 24th. ValuEngine raised shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Finally, Pivotal Research downgraded shares of USANA Health Sciences from a “buy” rating to a “hold” rating and set a $95.00 price objective for the company. in a report on Monday, April 23rd. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. USANA Health Sciences presently has an average rating of “Hold” and an average price target of $95.00.
In other USANA Health Sciences news, major shareholder Global Ltd Gull sold 360,827 shares of the business’s stock in a transaction on Thursday, May 31st. The shares were sold at an average price of $112.61, for a total value of $40,632,728.47. Following the completion of the sale, the insider now directly owns 10,921,009 shares of the company’s stock, valued at $1,229,814,823.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Myron W. Wentz sold 4,144 shares of the business’s stock in a transaction on Wednesday, May 23rd. The stock was sold at an average price of $120.86, for a total transaction of $500,843.84. Following the completion of the sale, the director now directly owns 11,025,753 shares of the company’s stock, valued at $1,332,572,507.58. The disclosure for this sale can be found here. Over the last ninety days, insiders have bought 19,117 shares of company stock valued at $1,349,965 and have sold 1,054,810 shares valued at $117,978,219. Insiders own 48.00% of the company’s stock.
USANA Health Sciences Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA).
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.